PKO Investment Management Joint-Stock’s AbbVie ABBV Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.33M	Buy	21,200 +200	+1%	+$43K	0.39%	61
2026 Q1	$4.57M	Sell	21,000 -2,000	-9%	-$444K	0.38%	59
2025 Q4	$5.26M	Sell	23,000 -12,584	-35%	-$2.87M	0.42%	52
2025 Q3	$8.24M	Sell	35,584 -3,500	-9%	-$713K	0.7%	30
2025 Q2	$7.25M	Buy	39,084 +23,084	+144%	+$4.29M	0.78%	30
2025 Q1	$3.35M	Buy	16,000 +2,500	+19%	+$486K	0.38%	61
2024 Q4	$2.4M	Buy	13,500 +1,700	+14%	+$313K	0.3%	59
2024 Q3	$2.33M	Sell	11,800 -1,700	-13%	-$317K	0.29%	61
2024 Q2	$2.32M	Hold	13,500	–	–	0.29%	67
2024 Q1	$2.47M	Hold	13,500	–	–	0.29%	64
2023 Q4	$2.09M	Hold	13,500	–	–	0.26%	62
2023 Q3	$2.01M	Sell	13,500 -9,500	-41%	-$1.39M	0.27%	59
2023 Q2	$3.1M	Buy	23,000 +3,500	+18%	+$513K	0.38%	47
2023 Q1	$3.11M	Sell	19,500 -5,783	-23%	-$884K	0.41%	46
2022 Q4	$4.09M	Sell	25,283 -4,000	-14%	-$613K	0.59%	37
2022 Q3	$3.93M	Sell	29,283 -4,698	-14%	-$674K	0.67%	36
2022 Q2	$5.2M	Buy	33,981 +9,000	+36%	+$1.38M	0.75%	35
2022 Q1	$4.05M	Sell	24,981 -5,400	-18%	-$784K	0.49%	48
2021 Q4	$4.11M	Sell	30,381 -17,076	-36%	-$2.02M	0.46%	54
2021 Q3	$5.12M	Buy	47,457 +15,536	+49%	+$1.78M	0.61%	45
2021 Q2	$3.6M	Buy	31,921 +9,903	+45%	+$1.12M	0.45%	51
2021 Q1	$2.38M	Hold	22,018	–	–	0.38%	46
2020 Q4	$2.36M	Hold	22,018	–	–	0.4%	47
2020 Q3	$1.93M	Hold	22,018	–	–	0.37%	49
2020 Q2	$2.16M	Buy	22,018 +4,246	+24%	+$374K	0.49%	42
2020 Q1	$1.35M	Hold	17,772	–	–	0.46%	45
2019 Q4	$1.57M	Hold	17,772	–	–	0.39%	55
2019 Q3	$1.35M	Hold	17,772	–	–	0.34%	54
2019 Q2	$1.29M	Hold	17,772	–	–	0.33%	56
2019 Q1	$1.43M	Hold	17,772	–	–	0.38%	51
2018 Q4	$1.64M	Hold	17,772	–	–	0.46%	49
2018 Q3	$1.68M	Hold	17,772	–	–	0.34%	53
2018 Q2	$1.65M	Sell	17,772 -5,458	-23%	-$533K	0.34%	53
2018 Q1	$2.2M	Hold	23,230	–	–	0.49%	41
2017 Q4	$2.25M	Sell	23,230 -1,137	-5%	-$107K	0.56%	39
2017 Q3	$2.17M	Buy	24,367 +11,359	+87%	+$865K	0.58%	35
2017 Q2	$943K	Buy	13,008 +7,572	+139%	+$509K	0.32%	49
2017 Q1	$354K	Buy	+5,436	New	+$342K	0.16%	58

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

PKO Investment Management Joint-Stock's ABBV Position: Q2 2026 in Review

PKO Investment Management Joint-Stock increased its AbbVie (ABBV) stake by 0.95% in Q2 2026, buying an estimated $43K and bringing the position to 21,200 shares worth $5.33M. The position accounts for 0.39% of the portfolio, ranked #61.

PKO Investment Management Joint-Stock first reported a position in ABBV in Q1 2017 and has held it in 38 quarters since. The position peaked at $8.24M in Q3 2025. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

PKO Investment Management Joint-Stock held 21,200 shares of AbbVie worth $5.33M as of Q2 2026.
PKO Investment Management Joint-Stock bought 200 AbbVie shares in Q2 2026, an estimated $43K.
AbbVie made up 0.39% of PKO Investment Management Joint-Stock's portfolio in Q2 2026, its #61 holding.
PKO Investment Management Joint-Stock first reported a position in AbbVie in Q1 2017 and has held it in 38 quarters since.
PKO Investment Management Joint-Stock's AbbVie position peaked at $8.24M in Q3 2025.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on PKO Investment Management Joint-Stock's 13F filing for Q2 2026, filed 20 Jul 2026.